The FDA has accepted an investigational drug application for MIN-101, a 5-HT2a and sigma2 antagonist from Minerva Neurosciences, for treatment of schizophrenia, according to a company press release.
A randomized, placebo-controlled, double-blind European phase 2b trial of MIN-101 will be conducted among 244 individuals.
The trial will assess efficacy of the drug to treat negative symptoms of schizophrenia, including cognitive symptoms and overall symptomatology.
Results from the 12-week treatment are expected in the second quarter of 2016.
Sources:
Press release/ Marketing Release:
http://ir.minervaneurosciences.com/releasedetail.cfm?ReleaseID=948285